CPI is a key partner in H2020 consortium to develop Nanopharmaceuticals

The Centre for Process Innovation (CPI) is part of a consortium which will focus on the development and scale up of nanopharmaceutical production. Coordinated by Midatech Biogune, part of the UK based Midatech Pharma , the project aims to scale up an existing Gold Nanoparticle (GNP)  production process to meet the projected demands associated with Midatech’s clinical pipeline in endocrine and oncology therapies.

Specifically, this project will focus on the manufacture of insulin coated gold nanoparticles, that are being used in Midatech`s insulin delivery patch. The outcomes of the project will also support the development of nanoparticle based therapies to address other disease areas.

CPI will deploy its bioprocessing and chemistry expertise and facilities to support the manufacturing scale up of nanoparticle generation, insulin coating and final purification. The funding will also allow CPI to establish the infrastructure which other Nanopharmaceutical companies can access to support  process development and scale up.

The project will leverage and enhance the expertise and knowledge of the nine companies and academic centres of excellence across Europe that form the consortium, leaving a legacy that will support the further growth of this emerging high potential technology.

 Dr Chris Dowle, Director of Biologics at CPI said: “Helping to secure the funding for this project is a significant milestone for CPI.  Beating off competition from an extremely competitive environment, CPI was able to assist Midatech in gaining the relevant funding it needs to move forward with the project, an obstacle which is often difficult to overcome for an SME.  We are extremely proud to be able to work with Midatech and the other consortium members on what promises to be a very exciting project.”

Dr Jim Phillips, CEO of Midatech said: “We are delighted to have joined forces with CPI on this project, they have provided a high level support and are an ideal partner going forward together with the other consortium members. Midatech is looking forward to a highly productive and fruitful collaboration which will form a key part of our portfolio development.”

Consortium details

• Coordinator: Midatech Biogune (ES)
• Consortium: Centre for Process Innovation Limited (UK), Prochimia Surfaces SP.Z.O.O (PL), Galchimia S.A (ES), the University College Dublin and the National University of Ireland (IE), Applus S.A. LGAI Technological Center, S.A (ES), IFOM, Fondazione Istituto FIRC di Oncologia Molecolare (IT), and Ecole Polytechnique Federale de Lausanne (CH).